After Hours: Bristol-Myers shares rise on melanoma drug study

MarketWatch.com - Financial Services Industry News http://ift.tt/1jfFseg Bristol-Myers Squibb shares gain ground in the extended session after the drug maker ends a melanoma drug study early because data show higher survival rates in patients taking it.